ClinicalTrials.gg
Not yet recruitingNCT06990984Updated Jul 24, 2026

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

A Phase 2 interventional study of TTI-0102: cysteamine-pantetheine disulfide and D-Mannitol in Leigh Syndrome, sponsored by Thiogenesis Therapeutics, Inc.. Not yet recruiting. Open to participants aged 5 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Thiogenesis Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
5 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate oral TTI-0102 to evaluate its pharmacokinetics, safety, and preliminary efficacy in patients with Leigh syndrome spectrum, in three sequences. First sequence will be placebo-controlled and include 12 adolescents and adults weighing more than 40 kg. Second sequence will be open-label and include 3 adults and 3 children weighing 25-40 kg. Third sequence will also be open-label and will include 3 children weighing 20-25 kg. The main questions clinical trial aims to answer are:

  • Characterize the relationship between TTI-0102 drug levels by measuring

    1. cysteamine pharmacokinetic (PK) parameters
    2. pharmacodynamic (PD) efficacy measures
  • Generate a population PK model and determine dose level for later dosing groups
  • collect data to inform the design of a subsequent phase 2b/3 study of TTI-0102 in this patient population

Participants will be asked to:

  • Take the study drug twice daily for 12 weeks
  • Visit the clinic for checkups and testing 7 times in total: once prior to study drug dosing, then 5 times over the 12-week treatment period and one more time a month after the last study drug dose.
02

Conditions studied

  • Leigh Syndrome

Browse trials for

03

In context

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

This study's planned enrollment of 18 is below the median of 31 across 10 interventional studies indexed under Leigh Disease.

Browse Leigh Disease studies →

Lead sponsor

Thiogenesis Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 5 years to 55 years (inclusive) and weight-eligible, at the time of / assent and enrollment
  • Confirmed diagnosis of Leigh syndrome or Leigh-like disorder (Leigh syndrome spectrum [LSS]) with neurodevelopmental manifestations, which include documented developmental delay, developmental regression, or abnormal neurologic exam findings
  • Willing and able to comply with required study schedule and procedures, including daily TTI-0102 study drug dosing requirements, i.e., able to ingest solution orally
  • Adequate liver function as evidenced by total \< 1.5x (ULN) and liver function tests \< 3x ULN
  • Normal hematologic parameters defined as:

≥ 1.0 x 109/L count ≥ 100,000/mm3 (100 x 109/L) ≥ 9 g/dL

  • Non-fasting serum triglycerides \< 300 mg/dL and non-fasting serum cholesterol \< 300 mg/dL
  • Serum amylase and lipase \< 2x ULN
  • Adequate immunoglobulin levels as outlined below that, in the opinion of the investigator, will not place the patient at increased risk of infection:

IgG ≥ 200 mg/dL IgM ≥ 30 mg/dL IgA ≥ 10 mg/dL

  • All sexually-active participants must agree to use effective during study participation:

    1. Females of must agree to use effective contraception without interruption from 28 days prior to starting TTI-0102 through 30 days after last dose of TTI-0102; have a negative serum pregnancy test result at screening; and agree to ongoing urine pregnancy testing during the subsequent study period.
    2. Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of reproductive potential while participating in the study and through 30 days after the last dose of TTI-0102

Exclusion criteria

Exclusion Criteria:

  • Documented diagnosis of concurrent inborn errors of metabolism
  • Non-elective hospitalization related to their Leigh syndrome or mitochondrial disease within 60 days prior to screening
  • Treatment with taurine during the previous 30 days of screening, and not willing to discontinue for the duration of the study
  • Severe gastrointestinal disease including gastroparesis
  • Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
  • In the opinion of the investigator, clinically-significant or severe cardiac conditions, at the time of screening
  • History of drug or alcohol abuse
  • History of pancreatitis
  • Known or suspected to cysteamine
  • Allergy to any medicine containing mercaptamine, penicillamine, or known hypersensitivity to any of the study drug ingredients
  • Exposure to any within 30 days prior to the first dose of TTI-0102, except for the influenza and / or COVID-19 vaccines
  • Planned surgical procedure during the study period
  • Clinically-significant proteinuria that requires ongoing medical therapy
  • Patients who are breastfeeding and / or are pregnant
  • History of solid organ transplant or bone marrow transplant
  • Treatment with any drug, including an investigational drug for mitochondrial disease, within 30 days prior to receiving the first dose of TTI-0102
  • Patients with confirmed or suspected increased intracranial pressure, pseudotumor cerebri / idiopathic intracranial hypertension, and or papilledema
  • Currently active (other than adequately treated non-melanoma skin cancers, carcinoma in situ of the cervix, or other adequately treated carcinoma in situ) and / or ongoing treatment for malignancy are ineligible. Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for at least one year
  • Recent infection requiring systemic anti-infective treatment that was completed ≤ 14 days prior to screening
  • Uncontrolled diabetes mellitus, as defined by > 8%, despite adequate therapy
  • History of interstitial lung disease and / or pneumonitis
  • Known , active and / or infection(s)
  • Any uncontrolled psychiatric or medical condition which, in the opinion of the investigator, would interfere with the patient's safe participation in the study
  • Any other condition or prior therapy that in the opinion of the investigator would render the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol and / or likelihood of non-compliance with any study requirements
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    TTI-0102: cysteamine-pantetheine disulfide

    Drug: TTI-0102: cysteamine-pantetheine disulfide

  • Placebo comparator
    Placebo

    Drug: D-Mannitol

Interventions

06

What researchers measure

Primary outcomes

  1. PK: plasma cysteamine (Tmax)

    Measurement of cysteamine in plasma: Tmax

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

  2. PK: plasma cysteamine (Cmax)

    Measurement of cysteamine in plasma: Cmax

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

  3. PK: plasma cysteamine (Cmin)

    Measurement of cysteamine in plasma: Cmin

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

  4. PK: plasma cysteamine (PK curve)

    Measurement of cysteamine in plasma: PK curve

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

  5. PK: plasma cysteamine (AUC)

    Measurement of cysteamine in plasma: AUC

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

  6. PD: plasma glutathione

    Measurement of glutathione concentration in plasma

    Time frame: Baseline (Day 1) to end of treatment (Day 84)

Secondary outcomes

  1. Safety and adverse events

    Number of participants with treatment-emergent adverse events \[comparing active vs. placebo\]

    Time frame: Baseline (Day 1) to final follow-up (Day 112)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — This is an exploratory study and we are not certain yet what data will be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 25, 2025
StartEst.
Oct 2026
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06990984
Lead sponsor
Thiogenesis Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Oct 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

TTI-LSS-001 Recruitment
Contact
clinreg@thiogenesis.com
+1 (858) 500-6621
Zarazuela Zolkipli-Cunningham, MBChB, MRCP
principal investigator · Children's Hospital of Philadelphia
Patrice Rioux, MD, PhD
study director · Thiogenesis Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cysteamine-pantetheine disulfide

Start the discussion